FWIW, Oppenheimer analyst Bret Holley said $ARIA will price CML drug ponatinib aggressively - near Tasigna/Sprycel
It would be good to hear about the Rida NDA sooner than later. I also think they might to consider raising some capital here ( but maybe they're holding out to partner ex-US rights to Ponatinib?)